These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38349430)

  • 1. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
    Kline K; Luetkens T; Koka R; Kallen ME; Chen W; Ahmad H; Omili D; Iraguha T; Gebru E; Fan X; Miller A; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Yared JA; Hardy NM; Rapoport AP; Dahiya S; Atanackovic D
    Cancer Immunol Immunother; 2024 Feb; 73(3):45. PubMed ID: 38349430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
    Karschnia P; Rejeski K; Winkelmann M; Schöberl F; Bücklein VL; Blumenberg V; Schmidt C; Blobner J; von Bergwelt-Baildon M; Tonn JC; Kunz WG; Subklewe M; von Baumgarten L
    Neurology; 2022 May; 98(21):884-889. PubMed ID: 35351785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
    Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
    Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
    Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
    Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
    Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
    Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
    Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
    J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
    Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
    Front Immunol; 2022; 13():965224. PubMed ID: 36059496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
    Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
    Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
    Zhang W; Huang C; Liu R; Zhang H; Li W; Yin S; Wang L; Liu W; Liu L
    Front Immunol; 2022; 13():983934. PubMed ID: 36275715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell therapy in large B cell lymphoma.
    Boardman AP; Salles G
    Hematol Oncol; 2023 Jun; 41 Suppl 1(Suppl 1):112-118. PubMed ID: 37294963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
    Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
    Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
    Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y
    Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.
    Yu T; Luo C; Zhang H; Tan Y; Yu L
    Front Immunol; 2023; 14():1139482. PubMed ID: 37449207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
    Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
    Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
    Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Tu S; Zhou X; Guo Z; Huang R; Yue C; He Y; Li M; Chen Y; Liu Y; Chang LJ; Li Y
    Front Oncol; 2019; 9():1350. PubMed ID: 31867275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.